Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
G1 Therapeutics Inc
(NQ:
GTHX
)
7.110
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about G1 Therapeutics Inc
< Previous
1
2
Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
August 15, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
August 15, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX
August 09, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
August 09, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
August 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
August 08, 2024
From
G1 Therapeutics
Via
GlobeNewswire
GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders
August 07, 2024
From
Halper Sadeh LLC
Via
Business Wire
Pharmacosmos Group to Acquire G1 Therapeutics
August 07, 2024
From
G1 Therapeutics; Pharmacosmos
Via
GlobeNewswire
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
July 25, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
June 24, 2024
From
G1 Therapeutics
Via
GlobeNewswire
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
May 28, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
May 23, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
May 22, 2024
- Jupiter Bioventures will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib for Radioprotection in the US, Europe, Japan, and All Other...
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
May 01, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
May 01, 2024
- Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding...
From
G1 Therapeutics
Via
GlobeNewswire
Biotech Innovations Paving the Way in Breast Cancer Fight
April 11, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Product Safety
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
February 28, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
February 12, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
December 05, 2023
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
November 29, 2023
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
November 01, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
October 27, 2023
Multiple Analyses Also Describe Significant Burden of Chemotherapy-Induced Myelosuppression and Impact on Healthcare Resource Utilization in ES-SCLC
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
October 18, 2023
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
October 16, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Black Diamond Therapeutics Announces CEO Transition
September 18, 2023
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
August 02, 2023
From
G1 Therapeutics
Via
GlobeNewswire
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
July 31, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
June 04, 2023
From
G1 Therapeutics
Via
GlobeNewswire
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
May 16, 2023
Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events
From
G1 Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.